Polyrizon Reports Preclinical Results For Intranasal Naloxone Hydrogel Showing Strong Permeation Kinetics, Stability & Mucoadhesion

Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating promising permeation kinetics that complement the Company's previously reported stability and mucoadhesion successes.

Following the positive mucoadhesion findings-where Polyrizon's formulation showed significantly enhanced persistence on ex-vivo nasal tissue compared to a marketed intranasal naloxone product (p < 0.0001) -the Company has completed a dedicated series of permeation studies using a validated artificial membrane system. These studies assessed the rate and extent of naloxone diffusion from Polyrizon's hydrogel in comparison with the commercially available reference product under controlled conditions.

Importantly, despite the improved mucoadhesion demonstrated by Polyrizon's formulation, permeation profiles remained rapid, with no statistically significant differences in permeation kinetics when compared to the marketed naloxone product. This indicates that the hydrogel's enhanced residence time on the nasal mucosa does not impede or delay drug permeation, potentially preserving the fast-acting characteristics required for emergency opioid overdose reversal.